Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer
Charles G. Drake, Russell K. Pachynski, Sumit K. Subudhi, Douglas G. McNeel, Emmanuel S. Antonarakis, Todd M. Bauer, Peter Lauer, Dirk Brockstedt, Daniel Patricia, Mark Wade, Enrique Zudaire, Nibedita Bandyopadhyay, Dolly A. Parasrampuria, Suzette Girgis, Gary E. Mason, Roland E. Knoblauch, Nicole Stone, Jeffrey R. Infante, Marco M. Gottardis, Lawrence Fong
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer'. Together they form a unique fingerprint.